Catalent, Inc. (NYSE:CTLT) Receives $53.58 Average PT from Brokerages

Catalent, Inc. (NYSE:CTLT) has earned an average rating of “Hold” from the thirteen analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $53.58.

CTLT has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Catalent from $37.00 to $45.00 and gave the company a “hold” rating in a research note on Tuesday, August 15th. TheStreet cut shares of Catalent from a “c” rating to a “d+” rating in a research note on Monday, June 12th. Wells Fargo & Company initiated coverage on shares of Catalent in a research note on Thursday, July 20th. They issued an “equal weight” rating and a $43.00 target price on the stock. Robert W. Baird upped their price target on shares of Catalent from $35.00 to $47.00 in a research note on Tuesday, June 13th. Finally, William Blair restated a “market perform” rating on shares of Catalent in a research note on Wednesday, August 30th.

Insider Transactions at Catalent

In other Catalent news, Director Michelle R. Ryan purchased 1,000 shares of the stock in a transaction on Thursday, August 31st. The shares were purchased at an average price of $49.98 per share, with a total value of $49,980.00. Following the acquisition, the director now directly owns 1,979 shares in the company, valued at approximately $98,910.42. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, Director Michelle R. Ryan bought 1,000 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was acquired at an average cost of $49.98 per share, for a total transaction of $49,980.00. Following the completion of the transaction, the director now directly owns 1,979 shares in the company, valued at approximately $98,910.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Steven L. Fasman sold 817 shares of the business’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $44.65, for a total transaction of $36,479.05. Following the completion of the transaction, the executive vice president now directly owns 73,789 shares of the company’s stock, valued at approximately $3,294,678.85. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,442 shares of company stock valued at $247,577. 0.58% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Catalent

A number of hedge funds and other institutional investors have recently bought and sold shares of CTLT. KB Financial Partners LLC purchased a new position in Catalent in the 1st quarter worth approximately $30,000. Compagnie Lombard Odier SCmA purchased a new position in Catalent in the 4th quarter worth approximately $34,000. FNY Investment Advisers LLC purchased a new position in Catalent in the 1st quarter worth approximately $34,000. Optiver Holding B.V. purchased a new position in Catalent in the 1st quarter worth approximately $35,000. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Catalent in the 1st quarter valued at $48,000.

Catalent Stock Down 1.0 %

Catalent stock opened at $49.17 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.27 and a current ratio of 1.78. The stock has a market cap of $8.86 billion, a PE ratio of -37.82, a price-to-earnings-growth ratio of 3.85 and a beta of 1.23. Catalent has a fifty-two week low of $31.45 and a fifty-two week high of $90.81. The firm’s 50-day simple moving average is $47.05 and its 200 day simple moving average is $49.12.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, August 29th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Catalent had a negative net margin of 5.43% and a positive return on equity of 3.24%. The firm’s revenue was down 15.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.12 earnings per share. Research analysts predict that Catalent will post 0.7 EPS for the current fiscal year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.